Seanergy Dermatology
Therapeutics for Atopic Dermatitis, Psoriasis, and Other Inflammatory Conditions
Company Overview
Snapshot
Founded in March 2018 by Eran Perry, Masanobu Ogawa, and Doron Friedman, Seanergy Dermatology operates with 1–10 employees. The company has secured funding across one round from one investor. In February 2020, Maruho Israel Innovation Fund participated in a funding round, underscoring investor confidence in the company's therapeutic approach.
Business overview
Seanergy Dermatology is a clinical-stage pharmaceutical company focused on developing topical therapeutics for inflammatory and other skin conditions. The company's core technology is based on a patented discovery involving a synergistic mechanism between anti-inflammatory APIs and sulphated polysaccharides extracted from algae. Seanergy Dermatology operates within the Health Tech & Life Sciences sector, specifically targeting the Pharmaceuticals market with its drug discovery and development efforts.
Company Intelligence Q&A
- What is Seanergy Dermatology's primary focus?
- Seanergy Dermatology is a clinical-stage pharmaceutical company developing topical therapeutics for inflammatory skin conditions such as Atopic Dermatitis and Psoriasis.
- When was Seanergy Dermatology founded?
- Seanergy Dermatology was founded in March 2018.
- Who are the founders of Seanergy Dermatology?
- The company was co-founded by Eran Perry, Masanobu Ogawa, and Doron Friedman.
- What is Seanergy Dermatology's core technology?
- Seanergy Dermatology's patented technology is based on a synergistic mechanism between anti-inflammatory APIs and sulphated polysaccharides extracted from algae.
- Which investor participated in Seanergy Dermatology's funding round?
- In February 2020, Maruho Israel Innovation Fund participated in a funding round for Seanergy Dermatology.